Renaissance Health Care, Inc. Awarded Group Health, Inc. (GHI) Contract for Disease Management of Chronic Kidney Disease.LEXINGTON, Mass. -- Renaissance Health Care, Inc. (Renaissance) today announced that it has been awarded a contract by Group Health, Inc. (GHI GHI Group Health Incorporated (HMO) GHI German Historical Institute (Washington, DC) GHI Ghost Hunters International GHI Geohazards International GHI Gustav Heinemann-Initiative ) to provide disease management for GHI's members who suffer from chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is . Renaissance is a National Committee for Quality Assurance National Committee for Quality Assurance Medical practice A private, not-for-profit organization which has become the leading accreditor of managed care plans; in site visits, NCQA reviewers evaluate a managed care plan in terms of quality management, physicians' (NCQA NCQA National Committee on Quality Assurance, see there ) accredited disease management company providing specialized services to kidney patients. Renaissance has demonstrated unparalleled results in renal disease management on a national basis. Renaissance CEO, Robert Farrell commented: "It is indeed an honor to have been chosen by GHI to provide chronic kidney disease management to its members. GHI is among the insurance industry leaders who have recognized the tremendous need to address the debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction effects of end stage renal disease on its members, and is making the commitment to provide help and support. We are pleased to work with GHI and we look forward to providing our program, achieving positive results and bringing significant benefits to the participants in our end stage renal disease program." About GHI Group Health Incorporated (GHI) is a statewide health insurer serving New Yorkers since 1937. GHI and its wholly-owned subsidiary, GHI HMO, provide health insurance and administrative services to more than 2.6 million people. GHI offers customers a variety of PPO, EPO, HMO, as well as prescription drug, dental, and vision plans. Throughout its history GHI has pioneered many of the programs that are now standard in the health insurance field. For additional information about GHI, please visit www.ghi.com. About Renaissance Health Care, Inc. Renaissance Health Care, Inc. started in 1996, and is the leading provider of Disease Management services for patients with CKD. Renaissance is a National Committee for Quality Assurance (NCQA) accredited renal disease management company providing specialized services to kidney patients. Renaissance has a national network of nurse care managers and an expanding national base of customer contracts that is ready for expansion. The corporate headquarters are located in Lexington, MA. For more information on Renaissance, visit www.usrenal.com. Renaissance Health Care, Inc. is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Fresenius Medical Care Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 37%-owned by the health care company Fresenius SE. North America (FMCNA), which is a subsidiary of Fresenius Medical Care AG (Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. : FME, FME3) (NYSE NYSE See: New York Stock Exchange : FMS, FMS-p). For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com. This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion